Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Moderna has collaborated with manufacturing solutions provider Catalent for large-scale, commercial fill-finish manufacturing of its Covid-19 vaccine candidate, mRNA-1273.
The manufacturing will be carried out at Catalent’s biologics facility in Bloomington, Indiana, US. Catalent agreed to deliver vial filling and packaging capacity, and additional staffing required for 24×7 manufacturing activities at the site to facilitate the production of an initial 100 million doses.